X4 PHARMACEUTICALS, INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
X4 PHARMACEUTICALS, INC (XFOR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.09M, a 312.57% increase year-over-year.
- X4 PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.41M, a 364.93% increase year-over-year.
- X4 PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $760.00K, a 58.24% decline year-over-year.
- X4 PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $748.00K, a 69.19% decline year-over-year.
- X4 PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $4.30M, a 47.61% decline from fiscal 2024.
- X4 PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $8.20M, a 5.56% decline from fiscal 2023.
- X4 PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $8.69M, a 67.09% increase from fiscal 2022.
- X4 PHARMACEUTICALS, INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $5.20M, a 15.87% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3.09M 10-Q · filed 2026-08-06 | $5.50M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.41M 10-Q · filed 2026-08-06 | |||||
| 2025-12-31 | $4.30M 10-K · filed 2026-03-17 | |||||
| 2025-09-30 | $760.00K 10-Q · filed 2025-11-05 | $1.51M derived: sum of 2 quarters · filed 2026-08-06 | $2.03M derived: sum of 3 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $748.00K 10-Q · filed 2026-08-06 | $1.27M derived: sum of 2 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $519.00K 10-Q · filed 2026-08-06 | |||||
| 2024-12-31 | $8.20M 10-K · filed 2026-03-17 | |||||
| 2024-09-30 | $1.82M 10-Q · filed 2025-11-05 | $4.25M derived: sum of 2 quarters · filed 2025-11-05 | $5.99M derived: sum of 3 quarters · filed 2025-11-05 | |||
| 2024-06-30 | $2.43M 10-Q · filed 2025-11-05 | $4.17M derived: sum of 2 quarters · filed 2025-11-05 | ||||
| 2024-03-31 | $1.74M 10-Q · filed 2025-11-05 | |||||
| 2023-12-31 | $8.69M 10-K · filed 2026-03-17 | |||||
| 2023-09-30 | $2.36M 10-Q · filed 2024-11-13 | $4.50M derived: sum of 2 quarters · filed 2024-11-13 | $6.15M derived: sum of 3 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $2.14M 10-Q · filed 2024-11-13 | $3.79M derived: sum of 2 quarters · filed 2024-11-13 | ||||
| 2023-03-31 | $1.65M 10-Q · filed 2024-11-13 | |||||
| 2022-12-31 | $5.20M 10-K · filed 2025-03-26 | |||||
| 2022-09-30 | $1.11M 10-Q · filed 2023-11-09 | $2.63M derived: sum of 2 quarters · filed 2023-11-09 | $4.09M derived: sum of 3 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $1.52M 10-Q · filed 2023-11-09 | $2.98M derived: sum of 2 quarters · filed 2023-11-09 | ||||
| 2022-03-31 | $1.46M 10-Q · filed 2023-11-09 | |||||
| 2021-12-31 | $6.18M 10-K · filed 2024-03-21 | |||||
| 2021-09-30 | $1.52M 10-Q · filed 2022-11-03 | $3.31M derived: sum of 2 quarters · filed 2022-11-03 | $4.57M derived: sum of 3 quarters · filed 2022-11-03 | |||
| 2021-06-30 | $1.80M 10-Q · filed 2022-11-03 | $3.06M derived: sum of 2 quarters · filed 2022-11-03 | ||||
| 2021-03-31 | $1.26M 10-Q · filed 2022-11-03 | |||||
| 2020-12-31 | $5.43M 10-K · filed 2023-03-21 | |||||
| 2020-09-30 | $2.24M 10-Q · filed 2021-11-04 | -$17.45M 10-Q · filed 2020-11-05 | $3.42M derived: sum of 2 quarters · filed 2021-11-04 | $4.03M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $1.17M 10-Q · filed 2021-11-04 | $1.79M derived: sum of 2 quarters · filed 2021-11-04 | ||||
| 2020-03-31 | $613.00K 10-Q · filed 2021-11-04 | |||||
| 2019-12-31 | $2.05M 10-K · filed 2022-03-17 | |||||
| 2019-09-30 | $691.00K 10-Q · filed 2020-11-05 | $1.12M derived: sum of 2 quarters · filed 2020-11-05 | $1.39M derived: sum of 3 quarters · filed 2020-11-05 | |||
| 2019-06-30 | $433.00K 10-Q · filed 2020-11-05 | $695.00K derived: sum of 2 quarters · filed 2020-11-05 | ||||
| 2019-03-31 | $262.00K 10-Q · filed 2020-11-05 | |||||
| 2018-12-31 | $759.00K 10-K · filed 2021-03-19 | $5.62M 10-K · filed 2019-03-11 | ||||
| 2018-09-30 | $198.00K 10-Q · filed 2019-11-07 | $343.00K derived: sum of 2 quarters · filed 2019-11-07 | $471.00K derived: sum of 3 quarters · filed 2019-11-07 | |||
| 2018-06-30 | $145.00K 10-Q · filed 2019-11-07 | $273.00K derived: sum of 2 quarters · filed 2019-11-07 | ||||
| 2018-03-31 | $128.00K 10-Q · filed 2019-11-07 | |||||
| 2017-12-31 | $492.00K 10-K · filed 2020-03-12 | $906.00K 10-K · filed 2019-03-11 | ||||
| 2016-12-31 | $644.00K 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |